What is Mounjaro?
Mounjaro (tirzepatide) is an injectable prescription drug approved by the FDA in May 2022 for treating type 2 diabetes in adults. It activates GLP-1 and GIP receptors in the body to boost insulin release, lower blood sugar, slow digestion, and reduce appetite, leading to weight loss as a common effect.[1]
How does Mounjaro work?
Tirzepatide mimics two gut hormones—GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—that regulate blood sugar and hunger. Administered weekly via subcutaneous injection (2.5 mg to 15 mg doses), it improves glycemic control more effectively than single GLP-1 drugs like semaglutide in clinical trials.[1][2]
Who makes Mounjaro and what does it cost?
Eli Lilly manufactures Mounjaro. List price starts at about $1,000 per month for a four-week supply, though patient assistance programs, insurance, or coupons can lower costs to $25 or less for eligible users.[1][3]
Mounjaro for weight loss: Is it approved?
Mounjaro is not FDA-approved for weight loss but is often prescribed off-label for obesity due to average losses of 15-20% body weight in trials. Eli Lilly's Zepbound (same drug, different branding) gained approval for chronic weight management in November 2023.[1][4]
Common side effects and risks
Most users experience nausea, diarrhea, vomiting, constipation, or stomach pain, which often fade over time. Serious risks include pancreatitis, gallbladder issues, low blood sugar (with other diabetes meds), thyroid tumors (in rodents, not confirmed in humans), and allergic reactions. It's not for type 1 diabetes or those with medullary thyroid carcinoma history.[1][2]
How does Mounjaro compare to Ozempic or Wegovy?
Mounjaro (tirzepatide) targets two hormones versus Ozempic/Wegovy (semaglutide), which target only GLP-1. Head-to-head trials show Mounjaro yields greater A1C reductions (2.3% vs. 1.9%) and weight loss (up to 22 lbs more). Both are weekly injections, but supply shortages affect semaglutide more.[2][4]
Patent status and generic timeline
Eli Lilly holds patents on tirzepatide through at least 2036, with some formulation patents extending to 2039-2042. No generics are approved; challenges from competitors like Viking Therapeutics are ongoing.[5]
Who should avoid Mounjaro?
Avoid if pregnant, breastfeeding, or with personal/family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. Monitor kidney function and dehydration risk.[1]
[1]: FDA Label - https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
[2]: NEJM Trial (SURPASS-2) - https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
[3]: Eli Lilly Pricing - https://www.mounjaro.com/savings-resources
[4]: FDA Approval (Zepbound) - https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
[5]: DrugPatentWatch - https://www.drugpatentwatch.com/p/tradename/MOUNJARO